Report found business relationships between telehealth and pharma companies may indirectly lead patients toward certain branded drugs ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

As two of the world's largest and most prolific drugmakers, Pfizer (PFE-0.54%) and AstraZeneca (AZN-0.30%) both have grand visions for how to grow even larger over the coming years. And with ...

AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR ...

Pfizer PFE has committed significant resources for the development of treatments in the fields of oncology, internal medicine, immunology, inflammation and vaccines. Over the past decade, Pfizer has ...

As of November 25, Pfizer's forward P/E ratio is just 8.8, considerably lower than Eli Lilly at 56.5 and AstraZeneca at 16.2. Pfizer also has a competitive price-to-book ratio of 1.54.